MK-677

MK-677, also written MK-0677 and marketed informally as Ibutamoren, is an orally active, non-peptide growth hormone secretagogue. It was developed by Merck in the 1990s as part of a search for small molecules that could stimulate the body's own growth hormone axis, and it acts as an agonist at the growth hormone secretagogue receptor, the same receptor later found to be the target of the natural hunger hormone ghrelin ^[4][6]. Chemically it is a spiroindane derivative that mimics ghrelin's signaling while remaining stable enough for once-daily oral dosing ^[4].

Functionally, MK-677 amplifies the natural, pulsatile release of growth hormone from the pituitary and raises circulating insulin-like growth factor 1 (IGF-1), rather than simply flooding the body with a flat level of hormone ^[1]. This profile attracted extensive clinical investigation for conditions marked by low growth hormone or muscle wasting, including the sarcopenia and frailty of aging, obesity, catabolic illness, and recovery from hip fracture ^[1][2].

The human evidence is unusually detailed for a compound in this category. A two-year randomized, placebo-controlled trial in healthy older adults found that MK-677 restored growth hormone and IGF-1 to the levels of healthy young adults and significantly increased fat-free mass, while a separate trial in obese men documented gains in lean mass and energy expenditure ^[1][2]. Prolonged treatment has also been reported to improve sleep quality ^[3].

Despite this research pedigree, MK-677 was never approved as a medicine; development did not clear the functional and safety hurdles required for its intended indications, in part because of effects on blood sugar. It is not approved by the US Food and Drug Administration and is sold as a research chemical, most commonly as an oral liquid or capsule ^[1].

MK-677 commonly increases appetite and can cause fluid retention and edema, mild lethargy, and reduced insulin sensitivity with higher fasting glucose; relevant for anyone diabetic or prediabetic. It is not approved for human use and is sold as a research chemical; long-term safety is not established.

MK-677 (ibutamoren) is an investigational growth hormone secretagogue with no formal drug-interaction labeling, but clinical trials consistently document that it raises IGF-1 and can reduce insulin sensitivity and elevate fasting glucose; this metabolic effect is a documented concern for people using insulin or oral antidiabetic agents, whose glycemic control may worsen. Trials also record transient increases in cortisol and prolactin. Because it acts at the ghrelin receptor rather than through cytochrome P450 pathways, no CYP-based interactions are established. Any pairing with QT-affecting or metabolically active drugs remains theoretical rather than characterized. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

MK-677, later named Ibutamoren, was developed by Merck in the 1990s as an orally active, non-peptide growth hormone secretagogue; it emerged from a research effort to create small molecules mimicking the growth-hormone-releasing peptides, work that ran in parallel with the search that ultimately identified the natural hormone ghrelin and its receptor. Early clinical studies in the late 1990s documented its ability to raise growth hormone and IGF-1 and to improve sleep quality in both young and older adults ^[1]. Later trials, including a two-year randomized study in older adults, showed it could restore growth hormone secretion into the young-adult range and increase fat-free mass. Although never approved as a marketed drug, it is among the most thoroughly characterized compounds in the growth hormone space.

MK-677 is well regarded for combining a reliable, well-understood mechanism with the rare convenience of once-daily oral dosing rather than injection. It is valued in research and fitness communities for amplifying the body's own pulsatile growth hormone and IGF-1 output while preserving the natural rhythm of secretion, and its two-year data lifting older adults' hormone levels toward youthful ranges are frequently cited as a standout. It is honestly discussed as engaging its ghrelin-receptor target dependably, even where downstream functional benefits, such as in hip-fracture recovery, were not established. Recognized trade-offs include increased appetite, transient fluid retention, and reduced insulin sensitivity, which is why blood sugar warrants monitoring.